STOCK TITAN
  1. Home
  2. News
  3. AZN

Astrazeneca plc - AZN STOCK NEWS

Welcome to our dedicated news page for Astrazeneca plc (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on Astrazeneca plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astrazeneca plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astrazeneca plc's position in the market.

News
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
Rhea-AI Summary
GRAIL, in collaboration with AstraZeneca, will test samples from Japanese participants using its risk classification test on the Methylation Platform for lung adenocarcinoma. The study aims to show results within 10 days without tumor tissue, supporting future pharmaceutical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
News
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
Rhea-AI Summary
AstraZeneca expands savings programs for US inhaled respiratory portfolio, offering eligible patients to pay no more than $35 per month for medicines. The company aims to make inhalers more affordable for vulnerable patients with asthma and COPD. Starting June 1, 2024, patients can access this program for various respiratory medicines, including SYMBICORT. AstraZeneca emphasizes its commitment to addressing access and affordability barriers for patients with respiratory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
News
AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
Rhea-AI Summary
AstraZeneca initiates Phase III trial for BREZTRI AEROSPHERE to reduce severe cardiopulmonary outcomes in COPD patients. The ATHLOS trial also begins to compare BGF with other therapies on cardiopulmonary parameters. COPD's impact on global population and the increased risk of cardiopulmonary events are highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
clinical trial
News
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan shows significant improvement in progression-free survival in lung and breast cancer. European Medicines Agency validates marketing authorization applications for the drug in two types of cancer, based on phase 3 trial results. The drug aims to replace conventional chemotherapy in the treatment of multiple cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
News
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
Rhea-AI Summary
Positive results from the MANDARA Phase III trial for FASENRA in patients with EGPA were published, showing that FASENRA enabled patients to taper off oral corticosteroids while preventing relapses. The trial demonstrated that more than half of patients achieved remission with eosinophil-targeting biologic therapies, with benralizumab meeting the primary endpoint and showing non-inferior rates of remission compared to mepolizumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
clinical trial
-
News
TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
Rhea-AI Summary
AstraZeneca's TAGRISSO shows significant progression-free survival benefit in Stage III lung cancer patients with EGFR mutations, positioning it as a potential targeted treatment option. The LAURA Phase III trial results indicate a favorable trend in overall survival, with TAGRISSO demonstrating impactful clinical benefit in a potentially curative setting. Safety and tolerability profiles remain consistent, with ongoing investigations in neoadjuvant and adjuvant settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's Biologics License Application for datopotamab deruxtecan has been accepted in the U.S. for the treatment of nonsquamous non-small cell lung cancer. The application is based on results from the TROPION-Lung01 phase 3 trial, showing significant improvements in progression-free survival compared to standard care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
Rhea-AI Summary
AstraZeneca's TAGRISSO with chemotherapy has been approved in the US for EGFRm NSCLC treatment based on FLAURA2 results, showing significant PFS improvement. The addition of chemotherapy reduced the risk of disease progression by 38% compared to monotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
AstraZeneca Full year and Q4 2023 Financial Results
Rhea-AI Summary
AstraZeneca reports strong financial performance for FY 2023 with a 6% increase in total revenue, driven by double-digit growth in oncology, CVRM, R&I, and rare disease. Core EPS increased by 15% to $7.26, and a second interim dividend of $1.97 per share was declared. The company expects a low double-digit to low teens percentage increase in total revenue and core EPS for FY 2024. Key milestones include three new molecular entities approved and multiple international approvals for various medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
earnings
News
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
Rhea-AI Summary
SOPHiA GENETICS and AstraZeneca Spain have expanded their HRD testing program in Spain to support the molecular diagnosis of ovarian cancer. The program aims to increase access to local testing for homologous recombination deficiency (HRD) throughout the country, with the goal of making vital testing available to thousands more patients. AstraZeneca Spain has named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain, offering the option for HRD testing to become available to more laboratories. The collaboration aims to increase accelerated diagnostics for patients and support clinicians in precision treatment planning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
Stock AZN logo
Astrazeneca plc

Nasdaq:AZN

AZN Rankings

#39 Ranked by Market Cap
#1673 Ranked by Stock Gains
#1158 Ranked by Dividends

AZN Stock Data

212.97B
1.54B
0.01%
16.8%
0.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Cambridge

About AZN

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.